What is the relationship between zoltuximab/veluoximab and zolbetuximab

Zolbetuximab（zolbetuximab)-Vyloy and zolbetuximab are actually the same drug, but they are named differently. Zolbetuximab is the international nonproprietary name (INN) of the drug, which is used in global scientific research, clinical trials and academic exchanges, while "Veloyi" is the trade name of the drug in the Chinese market and is used for clinical prescriptions and drug sales. The name zotuximab is mostly used in Chinese literature. It is another name for the drug in academic and clinical terms based on the translation and naming method of the drug's structural and functional characteristics. Generally speaking, whether it is zoltuximab, veluoximab or zolbetuximab, they essentially refer to the same targeted monoclonal antibody drug, and there is no difference in ingredients or effects between the three.

zolbetuximab is an innovative monoclonal antibody that targets Claudin 18.2 (CLDN18.2). CLDN18.2 belongs to a member of the tight junction protein family and has limited expression in normal gastric mucosa, but is overexpressed in most gastric cancers and some pancreatic cancer cells. This selective expression feature allows zolbetuximab to accurately identify tumor cells while minimizing damage to normal cells. By binding to CLDN18.2, zolbetuximab can induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby selectively killing cancer cells and achieving targeted therapy.

In terms of clinical application,zolbetuximab has been approved overseas for the treatment of patients with CLDN18.2-positive advanced gastric cancer and gastroesophageal junction adenocarcinoma, providing a new treatment option for unresectable advanced patients. In China, the drug is officially launched under the trade name "Veloyi", allowing domestic patients to directly obtain this innovative drug. As the first monoclonal antibody drug targeting CLDN18.2, Veroide is a milestone in the field of precision treatment of gastric cancer, providing clinicians with a new option for targeted treatment.

Reference materials:https://www.astellas.com/en/news/29401